https://doi.org/10.1038/s41375-021-01485-x
E
Emmanuelle Ferrant
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
112
Papers
2.0K
Citations
21
h-index
29
i10-index
Emmanuelle Ferrant is an academic researcher from Communauté urbaine de Lyon. The author has contributed to research in topics: Chronic Lymphocytic Leukemia Research & Lymphoma Diagnosis and Treatment & CAR-T cell therapy research. The author has an h-index of 21, co-authored 96 publications.
Papers by this author
worksEfficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia
2022 · Leukemia · 194 citations
Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells
2021 · Clinical Nuclear Medicine · 78 citations
https://doi.org/10.1097/rlu.0000000000003756
Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time?
2025 · Leukemia · 11 citations
https://doi.org/10.1038/s41375-025-02605-7
Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups
2016 · Blood Cancer Journal · 5 citations
https://doi.org/10.1038/bcj.2015.115
PCR91 Patient Reported Outcomes in BRUIN CLL-321: A Phase 3 Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
2025 · Value in Health · 1 citations
https://doi.org/10.1016/j.jval.2025.04.1411
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat